AstraZeneca Signs an Agreement with Sobi to Buy its Priority Review Voucher for $95M

 AstraZeneca Signs an Agreement with Sobi to Buy its Priority Review Voucher for $95M

AstraZeneca Signs an Agreement with Sobi to Buy its Priority Review Voucher for $95M

Shots:

  • Sobi to sell its US FDA’s Priority Review Voucher to AstraZeneca for $95M in cash. The PRV was acquired as part of the acquisition of the emapalumab from Novimmune in July’2019
  • The PRV entitles the holder to FDA priority review of a single NDA or BLA which reduces the target review time leading to an expedited approval. The transaction is subject to clearance under HSR Antitrust Improvements Act
  • Emapalumab (marketed as Gamifant) is an anti-interferon-gamma (IFN-ɣ) mAb used for the treatment of hemophagocytic lymphohistiocytosis and has received FDA’s ODD, BT, rare pediatric disease designation and EMA’s PRIME designation

Source 1, Source 2 to­ read full press release/ article | Ref: AstraZeneca, Sobi | Image: Tfod

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post